These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30093071)

  • 21. Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1.
    Yuan XL; Chen L; Zhang TT; Ma YH; Zhou YL; Zhao Y; Wang WW; Dong P; Yu L; Zhang YY; Shen LS
    World J Gastroenterol; 2011 Apr; 17(15):2019-27. PubMed ID: 21528082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells.
    Gauthy E; Cuende J; Stockis J; Huygens C; Lethé B; Collet JF; Bommer G; Coulie PG; Lucas S
    PLoS One; 2013; 8(9):e76186. PubMed ID: 24098777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing.
    Sun L; Jin H; Li H
    Oncotarget; 2016 Jul; 7(27):42826-42836. PubMed ID: 27095576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of lysosome metabolism-meditated GARP/TGF-β1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.
    Ma J; Chen Y; Li T; Cao Y; Hu B; Liu Y; Zhang Y; Li X; Liu J; Zhang W; Niu H; Gao J; Zhang Z; Yue K; Wang J; Bao G; Wang C; Wang PG; Zou T; Xie S
    Oncogene; 2024 Jun; 43(25):1930-1940. PubMed ID: 38698265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.
    Lecomte S; Devreux J; de Streel G; van Baren N; Havelange V; Schröder D; Vaherto N; Vanhaver C; Vanderaa C; Dupuis N; Pecquet C; Coulie PG; Constantinescu SN; Lucas S
    Blood; 2023 Feb; 141(5):490-502. PubMed ID: 36322928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-GARP Antibodies Inhibit Release of TGF-β by Regulatory T Cells via Different Modes of Action, but Do Not Influence Their Function In Vitro.
    Igney FH; Ebenhoch R; Schiele F; Nar H
    Immunohorizons; 2023 Mar; 7(3):200-212. PubMed ID: 36928178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of Circulating CD4⁺CD25⁺GARP⁺ regulatory T cells in patients with acute coronary syndrome.
    Meng K; Zhang W; Zhong Y; Mao X; Lin Y; Huang Y; Lang M; Peng Y; Zhu Z; Liu Y; Zhao X; Yu K; Wu B; Ji Q; Zeng Q
    Cell Physiol Biochem; 2014; 33(3):621-32. PubMed ID: 24603196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
    de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S
    Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies.
    Guo J; Niu Z; Lv R; Yuan J; Zhang Z; Guan X; Li D; Zhang H; Zhao A; Feng J; Liu D; Zhou X; Gong J
    Int Immunopharmacol; 2024 Mar; 130():111782. PubMed ID: 38442579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA.
    Dedobbeleer O; Stockis J; van der Woning B; Coulie PG; Lucas S
    J Immunol; 2017 Jul; 199(2):391-396. PubMed ID: 28607112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.
    Su H; Ye DQ; Wang BL; Fang XH; Chen J; Wang Q; Li WX; Zhang N
    Br J Dermatol; 2008 Jun; 158(6):1197-209. PubMed ID: 18410422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of immunosuppressive mechanisms in a mouse glioma model.
    Ksendzovsky A; Feinstein D; Zengou R; Sharp A; Polak P; Lichtor T; Glick RP
    J Neurooncol; 2009 May; 93(1):107-14. PubMed ID: 19430886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GP96 is a GARP chaperone and controls regulatory T cell functions.
    Zhang Y; Wu BX; Metelli A; Thaxton JE; Hong F; Rachidi S; Ansa-Addo E; Sun S; Vasu C; Yang Y; Liu B; Li Z
    J Clin Invest; 2015 Feb; 125(2):859-69. PubMed ID: 25607841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance.
    Zhang W; Zhang D; Shen M; Liu Y; Tian Y; Thomson AW; Lee WP; Zheng XX
    J Immunol; 2010 Oct; 185(8):4750-9. PubMed ID: 20844194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulated immunity in PID patients with low GARP expression on Tregs due to mutations in LRRC32.
    Lehmkuhl P; Gentz M; Garcia de Otezya AC; Grimbacher B; Schulze-Koops H; Skapenko A
    Cell Mol Immunol; 2021 Jul; 18(7):1677-1691. PubMed ID: 34059789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
    Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
    Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.
    Han Y; Yang Y; Chen Z; Jiang Z; Gu Y; Liu Y; Xu S; Lin C; Pan Z; Zhou W; Cao X
    J Mol Med (Berl); 2014 May; 92(5):539-50. PubMed ID: 24668348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal immunization with heat shock protein 60 induces CD4(+) CD25(+) GARP(+) and type 1 regulatory T cells and inhibits early atherosclerosis.
    Zhong Y; Tang H; Wang X; Zeng Q; Liu Y; Zhao XI; Yu K; Shi H; Zhu R; Mao X
    Clin Exp Immunol; 2016 Mar; 183(3):452-68. PubMed ID: 26452441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
    Abd Al Samid M; Chaudhary B; Khaled YS; Ammori BJ; Elkord E
    Oncotarget; 2016 Mar; 7(12):14083-94. PubMed ID: 26885615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.
    Fan H; Yang J; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Gao F; Liu M
    Immunology; 2012 Jun; 136(2):218-30. PubMed ID: 22348606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.